CTAS vs PDSB · P/E 51, rev $11.26B vs $50.7M cap
Cintas Corporation (CTAS) versus PDS Biotechnology Corp (PDSB) — a side-by-side from cached financials, not a winner call.
Cintas Corporation (CTAS) is a specialty business services company listed on US.
PDS Biotechnology Corp (PDSB) is a biotechnology company listed on NASDAQ.
Latest reported CTAS revenue for 2026-05-31 was $11.26B. Net income was $2.00B. Revenue was up 8.9% from 2025-05-31 to 2026-05-31. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
PDSB does not have a complete income-statement cache yet.
CTAS currently screens at market cap $89.01B and trailing P/E 51.3. PDSB currently screens at market cap $50.7M.
Not investment advice. Open the CTAS and PDSB stock pages for the full models.
Not investment advice.